Polymorphisms of brain - derived neurotrophic factor genes are associated with anxiety and body mass index in fibromyalg
- PDF / 969,237 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 19 Downloads / 152 Views
BMC Research Notes Open Access
RESEARCH NOTE
Polymorphisms of brain‑derived neurotrophic factor genes are associated with anxiety and body mass index in fibromyalgia syndrome patients Boya Nugraha1*† , Sumadi Lukman Anwar2†, Christoph Gutenbrunner1 and Christoph Korallus1
Abstract Objective: Fibromyalgia syndrome has been associated with familial clusters although the specific genetic predisposition is not clear. Accordingly, studies concerning genetic factors associated with this disease are important. Brainderived neurotrophic factor (BDNF) has been shown to play a role in patients with fibromyalgia syndrome, particularly in mediating manifestations of pain and mood-related symptoms. Research on genetic factors, including genetic variations or single nucleotide polymorphisms, especially related to BDNF in fibromyalgia is very limited. Therefore, this study was aiming at determining the association of polymorphisms of BDNF, particularly rs2049046 (A>T) and rs7124442 (A>G), with body mass index (BMI) and mood-related symptoms in FMS. Results: In fibromyalgia syndrome cases, BDNF polymorphisms were associated with body mass index and anxiety score, specifically rs7124442 (A>G) (Fisher’s exact test χ2; p T) (Fisher’s exact test χ2; p 0.05; OR: 1.02). Additionally, the Hardy– Weinberg equilibrium of rs2049046 and rs7124442 in both patients and HC were not significantly different. Table 3 shows the genotype distribution of each of the BDNF SNPs and clinical scores in patients with FMS. Significant difference was found in rs2049046 in anxiety score, but no differences in other clinical symptoms, such as pain fatigue, number of tender points, BMI and depression. FMS patients with lower anxiety score have TT genotype at rs2049046. In rs7124442, there were no significant differences in all clinical symptoms. Table 3 also shows the genotype distribution of the two BDNF SNPs, patients with FMS were sub-grouped according to their BMI, anxiety and depression scores. Significant differences were found in BMI of rs7124442 and anxiety of rs2049046, but not in the subgroup of depression.
Discussion
Pathogenesis of FMS is still not clear and need to be elucidated further. Studying genetic abnormalities in this group of patients are important and relevant. Thus, the purpose of the study was to elucidate the abnormalities of BDNF in patients with FMS from a genetic perspective. BDNF has been known to play a role in the neuronal system, including neuronal development and synaptic functions. Polymorphisms or variants of BDNF are associated with different types of diseases which reflect its involvement in neuronal function. The association of BDNF in chronic pain, including patients with FMS has been well-known. In this study, we observed no significant differences of BDNF between patients with FMS and healthy subjects at SNPs rs2049046 and rs7124442, which had not been determined previously in FMS. Some association has already been found in
Table 3 Genotype distribution of two BDNF SNPs of FMS and its clinical features Clinic
Data Loading...
